10-K/A: Innoviva Amends 10-K, Reveals Armata's Going Concern Warning

Sentiment:

Annual Report Amendment 27 March 2026 4:01 PM

Innoviva, Inc. filed an amended annual report to include the audited financial statements of its subsidiary, Armata Pharmaceuticals, Inc., which reported substantial losses and a going concern doubt.

Capital raiseArmata entered into a Capital on Demand Sales Agreement on December 1, 2025, with JonesTrading Institutional Services LLC, allowing it to offer and sell shares of its common stock having an aggregate offering price of up to $100,000,000.The company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements.

Worse than expectedArmata's net loss significantly widened to $173.8 million in 2025 from $18.9 million in 2024, primarily due to a $121.0 million loss on the fair value of the Convertible Loan.The company reported an accumulated deficit of $501.5 million as of December 31, 2025.Armata explicitly stated substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.

Summary

Innoviva, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include the Audited Consolidated Financial Statements of its subsidiary, Armata Pharmaceuticals, Inc. (Armata).
Armata Pharmaceuticals, a clinical-stage biotechnology company, reported a significant net loss of $173.8 million for the year ended December 31, 2025, a substantial increase from $18.9 million in 2024.
The company has an accumulated deficit of $501.5 million as of December 31, 2025, and its existing cash and cash equivalents of $8.7 million are insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
Armata's total liabilities surged to $295.5 million in 2025 from $134.5 million in 2024, primarily due to a $121.0 million loss on the fair value of its Convertible Loan.
Innoviva Strategic Opportunities LLC (Innoviva SO), a wholly owned subsidiary of Innoviva, is Armata's principal stockholder (68.8% equity) and has provided $115.0 million in total debt financing to Armata during 2023, March 2024, and March and August 2025.
Armata entered into a Capital on Demand Sales Agreement on December 1, 2025, to potentially sell up to $100 million in common stock to raise additional capital.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to Armata's explicit going concern warning, a substantial increase in net loss, and heavy reliance on related-party debt, indicating significant financial distress for the subsidiary.

Positives

Armata's operating loss improved to $(36.6) million in 2025 from $(42.4) million in 2024.
Research and development expenses decreased to $23.7 million in 2025 from $34.4 million in 2024.
General and administrative expenses decreased to $12.4 million in 2025 from $13.2 million in 2024.
Armata continues to receive grant funding, with $4.9 million in grant and award revenue in 2025, supporting its AP-SA02 clinical study.

Negatives

Armata Pharmaceuticals reported a net loss of $173.8 million for the year ended December 31, 2025, significantly wider than the $18.9 million loss in 2024.
The company has an accumulated deficit of $501.5 million as of December 31, 2025.
Armata's existing cash and cash equivalents of $8.7 million as of December 31, 2025, are not sufficient to fund its operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
Total liabilities increased significantly to $295.5 million in 2025 from $134.5 million in 2024.
A $121.0 million loss was recognized from the change in fair value of the Convertible Loan in 2025.
Interest expense increased to $16.6 million in 2025 from $10.7 million in 2024.
An impairment expense of $5.4 million was recognized in 2025 related to certain operating lease right-of-use assets.

Risks

Substantial doubt exists about Armata's ability to continue as a going concern due to recurring losses and insufficient cash to fund operations for the next 12 months.
Inability to secure additional financing in a timely manner or on favorable terms could force Armata to delay, reduce, or eliminate research and development programs or other operations.
Issuance of equity securities to raise additional funds may result in dilution for existing stockholders, and new equity securities may have superior rights, preferences, and privileges.
Raising additional funds through collaboration, licensing, or similar arrangements may require relinquishing valuable rights to potential products on unfavorable terms.
The company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and volatility in financial markets.

Future Outlook

Armata Pharmaceuticals expects to continue incurring substantial losses and its transition to profitability depends on the successful development, approval, and commercialization of product candidates. The company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and similar arrangements, to fund its operations.

Management Comments

Pavel Raifeld, Chief Executive Officer, certified that the Annual Report on Form 10-K/A does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading, and that the financial statements fairly present the financial condition, results of operations, and cash flows.
Stephen Basso, Chief Financial Officer, certified that the Annual Report on Form 10-K/A does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading, and that the financial statements fairly present the financial condition, results of operations, and cash flows.

Industry Context

StockSavvy.ai notes that Armata's explicit going concern warning and significant accumulated deficit highlight the inherent financial risks and capital intensity of clinical-stage biotechnology companies. While grant funding and related-party debt from Innoviva provide some support, the substantial net loss and the need for continuous capital raises underscore the challenges in bringing novel therapeutics like bacteriophage-based treatments to market. This situation reflects a broader industry trend where promising scientific endeavors often require extensive, long-term funding before achieving commercial viability, making them highly susceptible to market conditions and investor sentiment.

Legal Proceedings

The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management's opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.

Related Party Transactions

Innoviva Strategic Opportunities LLC (Innoviva SO), a wholly owned subsidiary of Innoviva, owns 68.8% of Armata's outstanding equity as of December 31, 2025.
Armata received $115.0 million in total debt financing from Innoviva SO during 2023, March 2024, and March and August 2025.
Innoviva designees represent three out of eight seats on Armata's Board of Directors.
The Convertible Loan ($30.0 million principal) and various Term Debts (2023 Loan, 2024 Loan, March 2025 Loan, August 2025 Loan) are all from Innoviva SO.
Innoviva SO holds outstanding warrants to purchase Armata's common stock, some of which were extended to January 26, 2031.

Stakeholder Impact

Shareholders face potential for significant dilution from future equity offerings to raise capital, and the value of their existing equity is significantly impacted by Armata's accumulated deficit and going concern risk.
Innoviva, as the parent company and primary creditor through Innoviva SO, faces substantial financial risk due to Armata's precarious financial health and going concern warning.
Employees' continued employment and benefits are dependent on Armata's ability to secure necessary funding and achieve commercialization goals.

Next Steps

Innoviva's definitive Proxy Statement for the 2026 Annual Meeting of Stockholders is expected to be filed not later than 120 days after December 31, 2025.
Armata plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and similar arrangements.
The MTEC Agreement, which funds Armata's AP-SA02 clinical study, is effective through March 31, 2026.
Maturity dates for Armata's Convertible Loan, 2023 Loan, 2024 Loan, and March 2025 Loan were extended to June 1, 2027.
Armata's August 2025 Loan matures on January 11, 2029.
Certain Innoviva SO warrants were amended to extend their expiration dates to January 26, 2031.

Key Dates

Date	Description
November 14, 2002	Collaboration Agreement between Innoviva and Glaxo Group Limited.
March 30, 2004	Strategic Alliance Agreement between Innoviva and Glaxo Group Limited.
May 11, 2004	Amended and Restated Investors Rights Agreement.
December 16, 2009	Amendment to Change in Control Severance Plan effective and 2009 Change in Control Severance Plan adopted.
November 29, 2010	Second Amendment to Amended and Restated Governance Agreement.
October 3, 2011	Amendment to Strategic Alliance Agreement.
February 8, 2012	2012 Equity Incentive Plan approved by the board of directors.
May 16, 2012	2012 Equity Incentive Plan approved by stockholders.
January 17, 2013	Base Capped Call Transaction.
January 18, 2013	Additional Capped Call Transaction.
January 24, 2013	Indenture for 2.125% Convertible Subordinated Note Due 2023.
March 3, 2014	Master Agreement, Collaboration Agreement Amendment, and Strategic Alliance Agreement Amendment with Theravance Biopharma, Inc. and Glaxo Group Limited.
May 31, 2014	Theravance Respiratory Company, LLC Limited Liability Company Agreement.
June 1, 2014	Employee Matters Agreement.
June 2, 2014	Transition Services Agreement and Tax Matters Agreement.
March 2, 2015	Amendment/Clarification to Transition Services Agreement.
July 29, 2015	First Amendment to 2009 Change In Control Severance Plan.
April 28, 2016	Amended and Restated Certificate of Incorporation.
August 7, 2017	Indenture for 2.50% Convertible Senior Notes due 2025.
July 26, 2018	Second Amendment to 2009 Severance Plan.
September 7, 2018	Offer Letter with Marianne Zhen.
February 19, 2020	Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.
March 10, 2020	Cystic Fibrosis Foundation (CFF) Award Agreement commenced.
May 20, 2020	Offer Letter between Innoviva, Inc. and Pavel Raifeld.
June 15, 2020	Medical Technology Enterprise Consortium (MTEC) Agreement entered.
December 11, 2020	Strategic Advisory Agreement with Sarissa Capital Management LP and Amended and Restated Limited Partnership Agreement of ISP Fund LP.
May 20, 2021	Share Repurchase Agreement with Glaxo Group Limited and Letter Agreement with Innoviva Strategic Partners LLC.
March 2, 2022	Capped Call Confirmation.
March 7, 2022	Indenture for 2.125% Convertible Senior Notes due 2028.
April 29, 2022	Offer Letter between Innoviva, Inc. and Pavel Raifeld.
May 1, 2022	2021 Lease payment start date for Los Angeles office and R&D space.
May 23, 2022	Agreement and Plan of Merger with Entasis Therapeutics and Amendment No. 1 to the Investor Rights Agreement.
July 10, 2022	Agreement and Plan of Merger with La Jolla Pharmaceutical Company and Support Agreement with Tang Capital Partners, LP.
July 13, 2022	Equity Purchase Agreement with Royalty Pharma Investments 2019 ICAV and Third Amendment to Collaboration Agreement.
September 29, 2022	MTEC Agreement modified to increase total award and extend term into Q3 2024.
January 1, 2023	Amended and Restated Bylaws effective.
January 10, 2023	Armata received Convertible Loan in the aggregate amount of $30.0 million from Innoviva SO.
February 13, 2023	Registration statement for resale of securities issued in connection with Convertible Credit Agreement originally filed.
February 23, 2023	Transition Agreement between Larry Edwards and Innoviva Specialty Therapeutics, Inc.
March 15, 2023	Amended and Restated Insider Trading Policy and Guidelines effective.
April 5, 2023	Release of Claims form signed by Larry Edwards.
April 6, 2023	Registration statement for resale of securities issued in connection with Convertible Credit Agreement declared effective by the SEC.
April 28, 2023	2023 Employee Stock Purchase Plan.
July 10, 2023	Armata entered into the 2023 Credit Agreement for a $25.0 million secured term loan facility.
July 28, 2023	Offer Letter between Innoviva, Inc. and Stephen Basso.
October 2, 2023	Innoviva Clawback Policy effective.
March 4, 2024	Armata entered into the 2024 Credit Agreement for a $35.0 million secured term loan facility.
July 29, 2024	MTEC Agreement modified to increase total award to $21.6 million and extend term into Q3 2025.
November 12, 2024	Armata amended the Convertible Credit Agreement and 2023 Credit Agreement, extending maturity to January 10, 2026.
December 31, 2024	Fiscal year ended for Armata Pharmaceuticals, Inc.
March 12, 2025	Armata entered into the March 2025 Credit Agreement for a $10.0 million loan and amended the Convertible, 2023, and 2024 Credit Agreements, extending maturity dates to March 12, 2026.
April 29, 2025	Armata received $4.65 million of additional non-dilutive award funding through MTEC, increasing total to $26.2 million, and MTEC Agreement extended to September 30, 2025.
June 30, 2025	Aggregate market value of Innoviva's voting and non-voting common equity held by non-affiliates was $1.26 billion.
July 2, 2025	MTEC Agreement modified to extend term to March 31, 2026.
August 11, 2025	Armata entered into the August 2025 Credit Agreement for a $15.0 million loan.
December 1, 2025	Armata entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC for up to $100,000,000 of common stock.
December 31, 2025	Fiscal year ended for Innoviva, Inc. and Armata Pharmaceuticals, Inc.
January 23, 2026	Armata amended the Convertible, March 2025, 2024, and 2023 Credit Agreements, extending maturity dates to June 1, 2027. Also, certain outstanding Innoviva SO warrants were amended to extend expiration dates to January 26, 2031.
February 13, 2026	74,073,646 shares of Innoviva's Common Stock outstanding.
February 25, 2026	Original Annual Report on Form 10-K filed by Innoviva, Inc.
March 25, 2026	Ernst & Young LLP's report date for Armata's consolidated financial statements for the year ended December 31, 2025.
March 27, 2026	Filing date of this Amendment No. 1 on Form 10-K/A.
January 26, 2031	Extended expiration date for certain Innoviva SO warrants.

Recommendation

sell

The filing reveals severe financial distress for Innoviva's key subsidiary, Armata Pharmaceuticals, including a substantial net loss of $173.8 million in 2025, an accumulated deficit exceeding $500 million, and an explicit "going concern" warning. Armata's reliance on related-party debt and the need for significant future capital raises, coupled with the risk of dilution and potential relinquishment of product rights, signals a highly precarious financial position. This information presents a significant negative outlook for Innoviva's investment in Armata, warranting a "sell" recommendation for investors concerned about the parent company's exposure to this struggling subsidiary.

Keywords

Innoviva, Armata Pharmaceuticals, 10-K/A, SEC Filing, Financial Statements, Going Concern, Biotechnology, Pharma, Debt Financing, Convertible Loan, Clinical Trials, Bacteriophage, AP-SA02, AP-PA02, Research and Development, SEC, NASDAQ

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.